Millennium Management’s C4 Therapeutics CCCC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
– Sell
-90,000
Closed -$200K – 6046
2025
Q3
$200K Buy
+90,000
New +$216K ﹤0.01% 5552
2022
Q2
– Sell
-75,400
Closed -$1.83M – 7008
2022
Q1
$1.83M Buy
+75,400
New +$1.83M ﹤0.01% 3971

Other funds holding CCCC

Millennium Management's CCCC Position: Q3 2026 in Review

Millennium Management increased its C4 Therapeutics (CCCC) stake by 24% in Q3 2026, buying an estimated $190K and bringing the position to 266,432 shares worth $887K. The position accounts for ﹤0.01% of the portfolio, ranked #4568.

Millennium Management first reported a position in CCCC in Q4 2020 and has held it in 22 quarters since. The position peaked at $24.3M in Q4 2021. 152 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Millennium Management held 266,432 shares of C4 Therapeutics worth $887K as of Q3 2026.
  • Millennium Management bought 51,046 C4 Therapeutics shares in Q3 2026, an estimated $190K.
  • C4 Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q3 2026, its #4568 holding.
  • Millennium Management first reported a position in C4 Therapeutics in Q4 2020 and has held it in 22 quarters since.
  • Millennium Management's C4 Therapeutics position peaked at $24.3M in Q4 2021.
  • 152 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Millennium Management's 13F filing for Q3 2026, filed 16 Nov 2026.